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Abstract
Background: Conidiobolus spp. (mainly C. coronatus) are the causal agents of rhino-facial conidiobolomycosis, a
limited soft tissue infection, which is essentially observed in immunocompetent individuals from tropical areas. Rare
cases of invasive conidiobolomycosis due to C. coronatus or other species (C.incongruus, C.lamprauges) have been
reported in immunocompromised patients. We report here the first case of invasive pulmonary fungal infection due
to Conidiobolus pachyzygosporus in a Swiss patient with onco-haematologic malignancy.
Case presentation: A 71 year-old female was admitted in a Swiss hospital for induction chemotherapy of acute
myeloid leukemia. A chest CT performed during the neutropenic phase identified three well-circumscribed lung
lesions consistent with invasive fungal infection, along with a positive 1,3-beta-d-glucan assay in serum. A
transbronchial biopsy of the lung lesions revealed large occasionally septate hyphae. A Conidiobolus spp. was
detected by direct 18S rDNA in the tissue biopsy and subsequently identified at species level as C. pachyzygosporus
by 28S rDNA sequencing. The infection was cured after isavuconazole therapy, recovery of the immune system and
surgical resection of lung lesions.
Conclusions: This is the first description of C. pachyzygosporus as human pathogen and second case report of
invasive conidiobolomycosis from a European country.
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Background
Conidiobolus spp. are filamentous fungi, which belong to
the phylum Entomophthoramycota and are responsible
for a human disease called conidiobolomycosis. These
fungi are insect parasites and can also be found in soil,
decaying vegetation and reptile or amphibian droppings
[1, 2]. Although Conidiobolus spp. seem to be ubiquitous
in the world, conidiobolomycosis is mainly a tropical dis-
ease as the fungus needs a high level of humidity (> 95%)
for germination and growth. The infection usually consists
of a rhinofacial cellulitis, which can lead to chronic facial
deformity in immunocompetent hosts [1–4]. Few cases of
disseminated infections involving multiple organs (lungs,
heart, kidneys, spleen or brain) have been reported in im-
munocompromised individuals, such as hematologic can-
cer patients or solid-organ transplant recipients [5–14].
While Conidiobolus coronatus represents the main
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pathogenic species in humans, C. incongruus and C. lam-
prauges have also been reported, especially in dissemi-
nated infections [2, 5, 7, 9, 13]. We report here a case of
C. pachyzygosporus invasive infection limited to the lungs
in a patient with acute myeloid leukemia, which was ac-
quired in Switzerland.
Case presentation
A 71 year-old female of Swiss origin was admitted at the
University Hospital of Lausanne (Switzerland) for a diag-
nosis of acute myeloid leukemia. She underwent induction
chemotherapy (cytarabine 200mg/m2 days 1–7 and
daunorubicin 60mg/m2 days 1,2 and 3, followed by ima-
tinib and then dasatinib 140mg qd from day 3) and triple
intrathecal chemotherapy (cytarabine, methotrexate,
hydrocortisone). Chemotherapy-induced neutropenia (i.e.
neutrophil count < 500/mm3) occurred 8 days later and
antifungal prophylaxis with fluconazole (400mg qd) was
started. On the same day, the patient developed febrile
neutropenia due to Streptococcus mitis bacteremia and
was treated with piperacillin-tazobactam. The patient had
persistent neutropenic fever despite broad-spectrum anti-
biotic therapy. Meanwhile, the monitoring of 1,3-d-beta-
glucan (BDG) in serum (Fungitell™, Associates of Cape
Cod, MA) performed twice weekly was positive on two
consecutive values (213 and 104 pg/ml on day 5 and 8 of
neutropenia, respectively). The galactomannan testing in
serum was negative. Fluconazole was then switched to
caspofungin (70mg on day 1, followed by 50mg qd). A
chest and abdominal computerized tomography (CT) per-
formed on day 9 of neutropenia revealed two well-
circumscribed opacities in the right superior lobe and an-
other smaller nodule in the right inferior lobe (Fig. 1).
Caspofungin was switched to liposomal amphotericin B
(5mg/kg qd). The BDG test turned negative 3 days after
the start of amphotericin B therapy. The patient recovered
from neutropenia after 11 days and a bronchoscopy with
broncho-alveolar lavage (BAL) was performed on the
same day. Cultures and galactomannan testing were nega-
tive in BAL fluid. Aspergillus fumigatus-specific PCR and
18S rDNA panfungal PCR, as previously described [15],
were also negative on this sample. Because of worsening
dyspnea, another CT was repeated 4 days after the initial
imaging, which showed an increase in size of the lung le-
sions with appearance of ground-glass opacity (Fig. 1).
Liposomal amphotericin B was switched to oral isavuco-
nazole (200mg tid on day 1 and 2, followed by 200mg
qd) because of renal failure potentially attributed to
amphotericin B, and a bronchoscopy with radial ultra-
sound assisted transbronchial biopsies was performed, as
previously described [16]. Histologic examination of the
lung biopsy showed bronchopulmonary parenchyma with
necrosis and presence of large and tortuous mycelia with
occasional septa at Grocott and periodic-acid-Schiff (PAS)
staining (Fig. 2a). Cultures and A. fumigatus-specific PCR
performed on the native lung tissue biopsy were negative,
Fig. 1 Chest CT imaging at different time points (day 0 = initial diagnosis) showing two nodular lesions in the upper right lobe (red arrows). The
graphs in the right panel show volumetric data of the two lesions (volume in mm3) at the different time points. Duration of neutropenia (neutrophil
count < 500/mm3) and sequence of antifungal therapy courses are shown below
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but the 18S rDNA panfungal PCR was positive at 1582
copies/ml for a Conidiobolus spp. with the highest score
for C. nanodes/lamprauges (Fig. 2b). In order to confirm
this result, DNA was extracted from the histopathologic
paraffin-embedded tissue showing the mycelial elements.
The 18S rDNA PCR was positive for a mold belonging to
the order Entomophthorales, but discrimination at genus/
species level was not possible. PCR targeting the 28S
rDNA, which has demonstrated good discrimination for
identification of Conidiobolus spp. at species level [17],
was performed on this sample and provided an optimal
score with 100% identity for Conidiobolus pachyzygos-
porus (Fig. 2b).
Further patient history revealed no particular expos-
ition within the last 2 years, except a travel in Madeira 3
months earlier. Abdominal and cranial CT did not show
evidence of dissemination to other organs. Isavuconazole
therapy was continued with trough plasma concentra-
tions within the expected therapeutic range (3.8 mg/l at
day 7 of therapy). Serial chest CTs performed on day 10
and 25 of antifungal therapy showed a significant regres-
sion of the size of the lung lesions (Fig. 1). The patient
was in oncological remission following induction chemo-
therapy and tyrosine kinase inhibitors (ponatinib, then
nilotinib) were maintained awaiting an allogeneic
hematopoietic stem cell transplantation. Considering the
high immunosuppressive risk associated with this pro-
cedure, it was decided to surgically remove the residual
lung lesions. Wedge resections of the three nodules were
performed. Isavuconazole was interrupted 1 week later
after a total of 2 months of antifungal therapy, because
of the development of hepatic test disturbances of
probable toxic origin. A chest CT performed 2months
after interruption of antifungal therapy did not show any
sign of recurrent disease.
Discussion and conclusions
We describe here a case of proven invasive fungal infec-
tion attributed to Conidiobolus pachyzygosporus in a pa-
tient with acute myeloid leukemia. Although the mold
was not isolated in cultures, the histopathologic descrip-
tion of large hyphae evocative of a zygomycetous mold
despite the presence of occasional septa is consistent
with previous histological descriptions of Entomophthor-
ales in human tissues [2, 8, 9, 12, 13]. Direct molecular
testing performed by 18S rDNA PCR on both the native
tissue biopsy and the DNA extracted from the paraffin-
embedded tissue led to the identification of a Conidiobo-
lus spp. Identification at species level was achieved by
28S rDNA sequencing with a highest score and unique
match with 100% identity for Conidiobolus pachyzygos-
porus. While 18S rDNA sequencing lacks discrimination
for species identification among fungi of the order Ento-
mophthorales, 28S rDNA amplification was shown to be
able to discriminate species among the genus Conidiobu-
lus, including C. pachyzygosporus [17]. This novel spe-
cies has been described for the first time in 2018 in
samples of plant detritus from China and has never been
associated with infections in humans up to now [17].
Our literature search identified only 10 cases of invasive
Conidiobolus infections including the current one
(Table 1). Most cases were disseminated infections in-
volving multiple organs and six of them were observed
Fig. 2 Grocott silver staining of the lung tissue biopsy showing large and tortuous hyphal elements with occasional septa (a). Results of PCR
analyses performed directly on the lung tissue biopsy (native tissue and following DNA extraction from the paraffin-embedded tissue): 18S rDNA
sequencing (upper panel) and 28S rDNA sequencing (lower panel). Sequences were matched using the basic local alignment search tool of the
National Center for Biotechnology Information (NCBI) (b)
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in patients with hematologic malignancies. Mortality was
high (about 70%).
Interestingly, the BDG marker in serum was positive
in our case. Analyses of the cell wall of Entomophthor-
ales suggest the presence of significant amount of 1,3-d-
beta-glucan [2]. Positivity of the BDG marker in serum
was previously reported in a case of C. lamprauges infec-
tion [9], but lack of BDG detection was reported in a
case of C. incongruus infection [14]. Therefore, data are
still scarce to assess the value of the BDG test for diag-
nosis and follow-up of conidiobolomycosis.
Conidiobolus spp. are notoriously resistant in vitro to
most antifungal agents, including azole drugs [18, 19]. In
the absence of isolation of the mold by conventional cul-
tures, we could not perform antifungal susceptibility
testing in this case. Therapeutic options were limited by
the previous nephrotoxicity attributed to liposomal
amphotericin B and isavuconazole was continued be-
cause of favorable clinical and radiological evolution.
Significant reduction of the lung lesions was observed
which could be attributed to the antifungal effect of isa-
vuconazole and/or neutrophil recovery. Finally, complete
surgical removal of the lung lesions was performed with-
out relapsing disease in follow-up. Our case highlights
the importance of multilayered therapeutic approaches
combining surgery, granulocyte transfusion and
Table 1 Case reports of invasive fungal infections due to Conidiobolus spp.
Year of
publication,
region/country
(reference)
Underlying conditions Organs affected Species Treatment (dose), duration and outcome
1970, West
Virginia (USA)
[7, 10]
1 year-old male, no underlying
conditions
Mediastinum, lungs,
pericardium
C. incongruus Deoxycholate amphotericin B (1 mg/kg/day), 10 weeks
Outcome: cure
1983, Thailand
[5]
20 year-old female, no
underlying conditions
Soft tissues (breast),
lungs, mediastinum,
liver, gastro-intestinal
tract
C. incongruus Co-trimoxazole (2 g/day), duration NS
Outcome: death
1990, Texas (USA)
[8]
29 year-old male, cocaine abuse Endocardium, blood,
skin, heart, lungs,
kidneys, brain, muscles
Conidiobolus
spp.
None
Outcome: death
1992, Mississippi
(USA)
[12]
64 year-old male, kidney
transplantation
Lungs, myocardium,
brain, kidney, thyroid
C. coronatus Deoxycholate amphotericin B (50 mg every other
day), until death
Outcome: death
1994, Maryland
(USA)
[13]
32 year-old female, lymphocytic
lymphoma with leukemic
transformation (neutropenia)
Lungs, pericardium C. incongruus Deoxycholate amphotericin B (0.5 mg/kg/day, then
1.5 mg/kg/day) and flucytosine (150mg/kg/day), until
death
Surgery
Outcome: death
2009, India
[11]
10 year-old female, T-cell acute
lymphoblastic leukemia
Sinus, soft tissues (facial) C. coronatus Amphotericin B (NS), until death
Surgery
Outcome: death
2010, Germany
[14]
78 year-old female,
myelodysplastic syndrome
Sinus, soft tissues (facial),
brain
C. incongruus Liposomal amphotericin B (200 mg/day), until death
Surgery
Outcome: death
2011, Japan
[9]
61 year-old male, mantle cell
lymphoma, allogeneic HSCT
Lungs, heart, spleen,
kidney, bladder, thyroid
C.
lamprauges
Micafungin (150 mg/day) and liposomal amphotericin
B (2.5 mg/kg/day), then intravenous voriconazole (6
mg/kg/day on day 1, then 4mg/kg/day) and
micafungin (150 mg/day), until death
Outcome: death
2018, Wisconsin
(USA)
[6]
15 year-old male, B-cell lympho-
blastic leukemia (neutropenia)
Sinus, lungs C. coronatus Liposomal amphotericin B (10 mg/kg/day) and
anidulafungin (1.5 mg/kg/day) and oral terbinafine
(250 mg twice per day), duration NS
Surgery, granulocyte transfusion
Outcome: cure
2019, Switzerland
(present case)
71 year-old, acute myeloid
leukemia (neutropenia)
Lungs Conidiobolus
spp.
Caspofungin (70 mg/day on day 1, then 50 mg/day),
then liposomal amphotericin B (5 mg/kg/day), then
oral isavuconazole (200mg three times per day on
day 1 and 2, then 200mg/day), 2 months
Surgery
Outcome: cure
NS Not specified
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antifungal therapy, as previously suggested for invasive
Conidiobolus infections [6].
While conidiobolomycosis is classically described as a
tropical disease, the rare cases of invasive infections in
hematologic cancer patients have been described in tem-
perate regions (USA, Japan, Europe). For most of them,
the causal agent was a Conidiobolus spp. other than C.
coronatus, (the main cause of rhinofacial conidiobolomy-
cosis in tropical areas) [6, 9, 13, 14]. While Conidiobolus
spp. are supposedly ubiquitous and have even been iso-
lated in environmental samples of northern European
countries [20], detection of Conidiobolus spp. from clin-
ical specimens has rarely been reported in Europe [14,
21]. The fact that Conidiobolus spp. require a high level
of humidity for their growth and development could ex-
plain why their pathogenicity is usually limited to trop-
ical areas [2]. Whether climate changes and global
warming may alter the epidemiology of invasive fungal
infections in the future, with emergence of tropical fungi
in temperate regions, remains an open question. It is
noteworthy that the present case occurred during a sum-
mer period, when an unusual heat wave took place in
Europe, including in Switzerland. Increasing use of mo-
lecular tools may also impact fungal epidemiology by re-
vealing novel fungal pathogens that could be missed by
conventional culture methods.
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